What specific regulatory warning has been linked to the Leukotriene Modifier drug Montelukast?
Answer
Rare but serious psychological reactions
Leukotriene Modifiers, such as Montelukast, Zafirlukast, and Zileuton, represent a class of non-steroidal medications used for long-term asthma control by inhibiting leukotrienes, which are inflammatory chemicals. While effective for symptom management for up to 24 hours, Montelukast carries a notable safety caution. Regulatory bodies have issued warnings regarding its potential link to rare instances of serious psychological reactions in some patients. This is a crucial distinction from the localized side effects associated with inhaled steroids, highlighting a central nervous system consideration for this specific class of controller medication.
Related Questions
What is the primary goal of a preventer inhaler in long-term asthma treatment?When is adjusting preventative treatment strongly indicated for an asthma patient?Which ICS medication is listed as a mono-therapy preventer, sometimes having a brown casing?What is the most common bronchodilator paired with an Inhaled Corticosteroid (ICS) in combination inhalers?What component is added to an ICS and LABA to create a triple therapy inhaler for very severe asthma?What specific regulatory warning has been linked to the Leukotriene Modifier drug Montelukast?Approximately how long may it take for ICS therapy to manifest its maximum protective effect through consistent daily use?What key feature defines Maintenance and Reliever Therapy (MART) regarding the inhaler used?What device is highly recommended for use with Pressurised Metered Dose Inhalers (MDIs) to improve lung delivery?What is the most effective preventative measure against local side effects like oral thrush from steroid inhalers?